Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
- Sponsor
- Medical University of Vienna
- Study ID
- NCT00261612
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Lymphoma, Mantle-Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- bortezomib — DRUG
- rituximab — DRUG
- dexamethasone — DRUG
- treatment protocol — PROCEDURE
Study Details
Mantle cell lymphoma (MCL) remains difficult to treat by standard treatment approaches. Novel drugs have shown promising results in early clinical evaluations. In the current trial, we investigate a combination of bortezomib (a proteasome inhibitor), rituximab (a monoclonal antibody), and dexamethasone in patients with MCL, who have already been pretreated by standard chemotherapy and show again signs of disease progression. The study objectives include remission rates, safety of this drug combination, and survival time.
Key Dates
- Start date
- Jan 31, 2005
- Status verified
- Oct 2006
- Completion
- Jan 31, 2007
Study Design
- Enrollment
- 16 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
response rate